

1. Record Nr.	UNINA9910814967903321
Autore	Giroux Gary A.
Titolo	Executive compensation : accounting and economic issues // Gary Giroux
Pubbl/distr/stampa	New York, New York (222 East 46th Street, New York, NY 10017) : , : Business Expert Press, , 2015
ISBN	1-60649-879-7
Edizione	[First edition.]
Descrizione fisica	1 online resource (212 p.)
Collana	Financial accounting and auditing collection, , 2151-2817
Disciplina	658.4072
Soggetti	Executives - Salaries, etc
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Part of: 2014 digital library.
Nota di bibliografia	Includes bibliographical references (pages 187-190) and index.
Nota di contenuto	Introduction to executive compensation -- Compensation basics -- Accounting for executive pay -- Historical perspective on executive pay -- Economic theory -- International comparisons -- The future of executive compensation -- Appendix 1. Microsoft proxy disclosures, 2013 -- Appendix 2. Microsoft 10-K stock compensation disclosures, 2013 -- Appendix 3. Pfizer 10-K disclosures, 2012 -- Timeline -- Glossary -- Notes -- References -- Index.
Sommario/riassunto	The chief executive officer (CEO) of a corporation and his or her executive team are responsible for the management of the business and its continued operating and financial success. The CEO and executive team are almost always highly compensated and the relative total compensation has mushroomed over time. Most of the compensation now is designed to be performance-based, but leading to charges that executives have incentives to manipulate corporate earnings and stock price in the short-term for their own self interests. The compensation at some companies became so egregious (Enron and other tech-bubble failures or Citigroup and other banks during the subprime meltdown) that compensation again became a major public policy issue subject to federal regulation. (Popular outrage and calls for government action against well-paid CEOs has been common at least since the 1930s.)

2. Record Nr.	UNINA9910830908803321
Titolo	Neuroprotection [[electronic resource]] : models, mechanisms and therapies // edited by Mathias Bahr
Pubbl/distr/stampa	Weinheim, : Wiley-VCH, c2004
ISBN	1-280-51966-5 9786610519668 3-527-60386-7 3-527-60431-6
Descrizione fisica	1 online resource (391 p.)
Altri autori (Persone)	BahrMathias
Disciplina	616.806
Soggetti	Nervous system - Diseases - Treatment Molecular neurobiology
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	Neuroprotection Models, Mechanisms and Therapies; Preface; Contents; List of Contributors; I Neurological Disorders - Epidemiology, Clinical Overview, and Model Systems; 1 Stroke; Abstract; 1.1 Introduction; 1.2 The Penumbra Concept; 1.3 Excitotoxicity; 1.4 Oxygen Free Radicals; 1.5 Tissue Acidosis; 1.6 Peri-infarct Depolarizations; 1.7 Inflammation; 1.8 Damage to the Blood-Brain-Barrier; 1.9 Programmed Cell Death and Apoptosis; 1.10 Ischemia-induced DNA Damage, DNA Repair, and p53 as Genotoxic Sensor; 1.11 Epigenetics; 1.12 Gene Expression; 1.13 Cell Replacement 1.14 Endogenous Neuroprotection - Ischemic Tolerance 1.15 Stroke Induced Immune Depression (SIDS); 1.16 Conclusion; References; 2 Parkinson's Disease; 2.1 Epidemiology of Parkinson's Disease; 2.1.1 Genetic Contribution; 2.1.2 Environmental Factors; 2.2 Oxidative Stress In Parkinson's Disease; 2.3 Role of Alpha-Synuclein in Parkinson's Disease; 2.3.1 Alpha-Synuclein in Lewy Bodies; 2.3.2 Alpha-Synuclein and Oxidative Stress; 2.4 The Involvement of Proteosome in PD; 2.4.1 Parkin Involvement in PD; 2.5 Other Genes Involved in Familial Parkinson's Disease; 2.6 Neurotoxic PD Models 2.6.1 Oxidative Stress 2.6.2 Dopamine Homeostasis/Complex I; 2.6.3

Proteasome; 2.7 Genetic Models of Parkinson's Disease; 2.7.1 Alpha-Synuclein Overexpressing Transgenic Animals; 2.7.2 Parkin-related Genetic Models; 2.7.3 Viral Vectors for In Vivo Gene Transfer of Disease-related Proteins to the CNS; 2.7.3.1 Local Overexpression of alpha-synuclein; 2.7.3.2 Local Overexpression of Parkin-related Proteins; Acknowledgements; References; 3 Amyotrophic Lateral Sclerosis; 3.1 Human Motor Neuron Diseases; 3.1.1 Familial ALS Linked to SOD1 Mutations; 3.1.2 Juvenile ALS Linked to Alsin Mutations 3.2 Cell Culture Models of Motoneuron Degeneration 3.2.1 Neuronal Cell Lines; 3.2.2 Isolated Motoneuron Cultures; 3.2.3 Organotypic Cultures; 3.3 Animal Models of Motor Neuron Disease; 3.3.1 Axotomy Models; 3.2 Mutant SOD1 Mice; 3.3.3 pmn Mice; 3.4 Future Neuroprotective Approaches; 3.4.1 Axonal Protection; 3.4.2 Mutant SOD1 Knockdown by RNA Interference; 3.5 Conclusion; References; 4 Alzheimer's Disease and Other Neurodegenerative Diseases; Abstract; 4.1 Introduction; 4.2 Transgenic Invertebrates; 4.3 Transgenic Mice; 4.3.1 Tyrosine Hydroxylase (TH) Promoter 4.3.2 Platelet-derived Growth Factor- (PDGF) Promoter 4.3.3 Thy1 Promoter; 4.3.4 Prion Protein (PrP) Promoter; 4.3.5 Glial Expression; 4.4 Viral Models; 4.5 Conclusion and Outlook; References; 5 CNS Inflammation; 5.1 Introduction; 5.2 The Pathologic Characteristics of the MS Plaque; 5.3 Axonal Pathology in MS; 5.4 Neuronal Pathology in Multiple Sclerosis; 5.5 Lessons from Animal Models; References; 6 Neurotrauma; 6.1 Introduction; 6.2 In Vivo Models; 6.2.1 Static Brain Injury Models; 6.2.2 Dynamic Brain Injury Models; 6.2.2.1 Indirect Dynamic Brain Injury; 6.2.2.2 Direct Dynamic Brain Injury 6.2.3 Combined Neurotrauma Models

Sommario/riassunto

In this first book to cover model systems, molecular mechanisms and clinical trials all in one volume internationally renowned scientists and clinicians provide a comprehensive treatment of neuroprotective strategies for all important neurological disorders. Following an overview of neurodegenerative, traumatic, and ischemic disorders, the book goes on to cover in vitro and animal model systems as well as cellular and molecular mechanisms. An extremely helpful analysis of clinical studies explains reasons for their success and failure, and the whole is rounded off with a look at the current
